145 related articles for article (PubMed ID: 38350336)
1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Michels S; Massutí B; Vasyliv I; Stratmann J; Frank J; Adams A; Felip E; Grohé C; Rodriguez-Abreu D; Bischoff H; Carcereny I Costa E; Corral J; Pereira E; Fassunke J; Fischer RN; Insa A; Koleczko S; Nogova L; Reck M; Reutter T; Riedel R; Schaufler D; Scheffler M; Weisthoff M; Provencio M; Merkelbach-Bruse S; Hellmich M; Sebastian M; Büttner R; Persigehl T; Rosell R; Wolf J
ESMO Open; 2024 Feb; 9(2):102237. PubMed ID: 38350336
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
Schneider JL; Muzikansky A; Lin JJ; Krueger EA; Lennes IT; Jacobson JO; Cheng M; Heist RS; Piotrowska Z; Gainor JF; Shaw AT; Dagogo-Jack I
JTO Clin Res Rep; 2022 Jul; 3(7):100347. PubMed ID: 35815322
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Entrectinib in
Drilon A; Chiu CH; Fan Y; Cho BC; Lu S; Ahn MJ; Krebs MG; Liu SV; John T; Otterson GA; Tan DSW; Patil T; Dziadziuszko R; Massarelli E; Seto T; Doebele RC; Pitcher B; Kurtsikidze N; Heinzmann S; Siena S
JTO Clin Res Rep; 2022 Jun; 3(6):100332. PubMed ID: 35663414
[TBL] [Abstract][Full Text] [Related]
6. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
7. Distinct metastatic spread and progression patterns in patients treated with crizotinib for
Nakamura T; Yoshida T; Takeyasu Y; Masuda K; Sinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
Transl Lung Cancer Res; 2023 Jul; 12(7):1436-1444. PubMed ID: 37577313
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
[TBL] [Abstract][Full Text] [Related]
10. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
13. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38280448
[TBL] [Abstract][Full Text] [Related]
14. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
[TBL] [Abstract][Full Text] [Related]
15. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
[TBL] [Abstract][Full Text] [Related]
18. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Huber RM; Hansen KH; Paz-Ares Rodríguez L; West HL; Reckamp KL; Leighl NB; Tiseo M; Smit EF; Kim DW; Gettinger SN; Hochmair MJ; Kim SW; Langer CJ; Ahn MJ; Kim ES; Kerstein D; Groen HJM; Camidge DR
J Thorac Oncol; 2020 Mar; 15(3):404-415. PubMed ID: 31756496
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Taletrectinib in Chinese Patients With
Li W; Xiong A; Yang N; Fan H; Yu Q; Zhao Y; Wang Y; Meng X; Wu J; Wang Z; Liu Y; Wang X; Qin X; Lu K; Zhuang W; Ren Y; Zhang X; Yan B; Lovly CM; Zhou C
J Clin Oncol; 2024 Jun; ():JCO2400731. PubMed ID: 38822758
[TBL] [Abstract][Full Text] [Related]
20. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
